BIEL SQUEEZE COMING!
Supply/Demand - the outstanding shares (almost 25 billion) are irrelevant as the overwhelming majority are in tight hands. The pps will move up like a rocket (after ignition - pr/news) as the supply of available shares will be less than the demand (SQUEEZE!) well into copper. The majority of shares currently available at the buy are shorts looking to make a quick 50% profit by selling at 3 and buying back at 2 (often in the same day). Any hint of good news will force the shorts to cover, which will get the pps momentum rolling upward.
Shareholders can help by locking up their shares with "good until cancelled" sell orders @$1/share so that their shares cannot be borrowed by the short sellers, thereby further reducing the supply. With a little news, BIEL could soar like 2021, or like silver did when the Hunt brothers cornered the market (by reducing the available supply).
BIEL GONNA RUN LIKE 2021! Everything is falling into place just like 2021. This is one instance where savvy investors do pay attention to "history". The technical indicators come first - the Golden Cross has been achieved and the Blue Sky Breakout is on the horizon. Then the fundamentals kick in (Taiwan, VA, Veterinary, New Zealand...). Hopefully, the Stanford carpal tunnel study will show the same excellent results as the Italian study that Hawk shared with us a few days ago!
The last bull run to .0088 started at the end of January 2021. The previous runs in 2017 and 2014 were also in the same time frame. Will history repeat itself - COPPER BY SPRING?
The past BIEL runs coincided with OTC bull markets, like the one that we are in now, as confirmed by Robinhood (favorite for OTC investors) stock outperforming Goldman Sachs (institutional favorite) 150% to 30% over the past few months.
SAVVY INVESTORS RECOGNIZE BIEL IS AN APPLE/AMAZON TYPE of INVESTMENT (in terms of ROI)
When BIEL hits .01, the return on investment for a .0003 buy will be greater than the 10 year ROI (>3,000%) for Amazon and Apple.
BIEL can hit copper in IN THE BLINK OF AN EYE, as $1.5 - 2 million annual revenue (or a $400k quarter) should do it, and there are many indications this will be accomplished soon, if not already!
Savvy investors recognize an Apple/Amazon opportunity when they see one, and BIEL is that OPPORTUNITY, the best on the market right now!
BIEL HITS COPPER "IN THE BLINK OF AN EYE" WHEN THE FOLLOWING OCCURS!
pps > .001 after management drops some positive hints. The Golden Cross (already achieved) and Blue Sky Breakout will get the technicians/chartists attention and the pps out of the trips;
pps > .01 after management drops some positive hints that convinces investors that break even/cash flow positive (annual rev = $1.5 mil) will be achieved, combined with the momentum from a 2021 like OTC run (Reddit crowd takes notice);
pps > .04 after pr indicates the annual revs from Taiwan (in progress) can be valued at $10 mil+;
pps > .08 after pr indicates the annual revs from the VA (in progress) can be valued at $10 mil+;
pps > .12 after pr indicates the annual revs from RecoveryRx Veterinary (pending) can be valued at $10 mil+;
pps > .16 after pr indicates the annual revs from new contracts (distributors, partners, New Zealand, etc.) can be valued at $10 mil+;
Above pps values are based on P/E = 100
For P/E = 200, pps = .32
For P/E = 300, pps = .48
pps > $1 after loans are paid off and a stock buyback is initiated.
CATALYSTS (Details):
$1.5 million annual revenue (or a $400k quarter) = break even, cash
flow positive: PPS = .01.
Q3 2021 was BIEL's only profitable quarter ($22,381) with $414,700 revenue (including $100k+ in covid relief funds). Profitability is very close. Seems like $1.5 million annual revenue (or a $400k quarter) should do it - and the corresponding pps should hit .01 - then increase .01 for each additional $2.5 million annual revenue (P/E = 100).
KISS - KEEP IT SIMPLE STUPID! 💋
Taiwan looks like it will be the first catalyst. There are over 80 public hospitals and over 400 private hospitals in Taiwan. They have national health insurance and are rated the world's number one health system.
Assume 100 Taiwan hospitals order 100 Actipatch/RecoveryRx per month @$100 each for BIEL:
$100 x 100 hospitals x 100 x 12 mo = $12,000,000 rev/year.
Using profit = $10 mil and P/E = 100: PPS = .04.
Note: RecoveryRx Veterinary also appears to be in play in Taiwan.
1000 Veterinarian Clinics (USA):
Conservatively assume each office orders 10/mo. @ $100 each for BIEL (Vet sells for $200, a bargain compared to Assisi):
1000 x 100 x 10 x 12 = $12,000,000 rev/year.
Note: RecoveryRx Veterinary also appears to be in play internationally.
There are over 1,000 VA facilities in the U.S. Conservatively assuming 100 VA hospitals order 100 RecoveryRx per month ($100 each for BIEL):
100 x 100 x 100 x 12 = $12,000,000 rev/year.
Sub-total for VA + VET = $20 mil and P/E = 100: PPS = .08!
TOTAL (Taiwan + VA + Veterinary + applying the tax loss carryforward):
pps = .12 (P/E = 100)
pps = .24 (P/E = 200)
pps = .36 (P/E = 300)
Additional revenue could be generated from new FDA clearances, vagus nerve patent, NPA, UK/Australia contract rumor, RecoveryRx Veterinary international sales, New Zealand, etc.
Initiating a stock buyback program after all of the loans are paid off would propel the pps much higher (pps = $1).
BIEL FACT CHECK:
1) The nearly 25 billion shares outstanding is large but not a problem and accounted for in the valuation (pps). 25 billion shares @.0002 = $5 million is the same valuation as 1 million shares at $5/share. FULL STOP
Some have tried to dispute this - without success - always changing the subject to dilution. BIEL has not diluted significantly in many years, and there is no indication it will in the future.
The low pps is actually an advantage at this point, as it makes BIEL affordable to any investor. If you have $1,200 to invest, would you rather own 6 million shares of BIEL or 1 share of O'Reilly Auto Parts?
2) BIEL's valuation is currently $5 million (for revs of $715k last year), which is undervalued compared to stocks (like SERV and QUBT for example) with billion-dollar valuations but only half of BIEL's revenue. FULL STOP
When people become aware of the benefits of PSWT/PEMF and the huge multi-billion-dollar drug free pain management market - that desperately needs FDA cleared Actipatch/RecoveryRx/RecoveryRx Veterinary- BIEL will SOAR!
3) BIEL has NEVER done a reverse split!
4) Apple will soon have billions more shares outstanding than BIEL!
DETRACTORS
There is a small but loud group of detractors intent on trashing BIEL. Since they are not investors, their reasons are unknown. Their leader is a past investor who has always made profits on his BIEL investment. His motivation for constantly trashing BIEL is unknown, although he may be trying to scare investors into selling so he can buy cheaper shares. His constant bashing contradicts his past positive posts, such as:
Post #323815 (11/7/23)
I have Staelin penned as a masterful business strategist. He MUST have a plan.
Post #324395 (11/27/23)
Forbes is legit. Now THERE is something worth promoting.
They list pros and cons, and the only real con is that you might need to wear it 12 hours per day... to which I say, bring it on. I have had back pain on and off for many years, caused by moving furniture for Mayflower in my 20's and basically abusing my back my whole life... I wear a back brace most of the time anyway. I'm sure that anyone with chronic back pain agrees with me.
Post #324816 (12/12/2023)
There's nothing so critically wrong with BIEL that it can't be fixed. This company isn't screwing shareholders the way ENDV is screwing shareholders, for example.
Post #325074 (12/22/2023)
Positives for BIEL:
1. It's a real company with a real product.
2. The company is not burning $$$ millions every quarter trying to get a product through the FDA wringer. They accomplished that already.
3. The company is very close to profitability every quarter. Just a stone's throw, really.
4. There is no toxic debt. The company is not sinking under death spiral financing.
Down here in the world of sub-penny pink biotech, EACH of these is the exception, not the rule. That makes BIEL.... exceptional!
Yes, BIEL also has its negatives, of which we are all aware. Every pinkie biotech has positives and negatives. But let's give credit where credit is due.
CONCLUSION: BIEL WILL CREATE BIELIONAIRES!!!
AI
